In the early part of this century, Otto Warburg postulated that tumours were acidic because the rate at which they produced lactic acid was ‘remarkable’ (Warburg, 1956). Subsequent measurement of pH in a variety of solid tumours with microelectrodes apparently confirmed this hypothesis (Wike-Hooley et al, 1984). It is assumed that microelectrode measurements primarily interrogate extracellular (interstitial) volumes. However, in-vivo 31P magnetic resonance spectroscopy (MRS) of endogenous intracellular inorganic phosphate (Pi) measures an intracellular pH (pHi) which is neutral-to-alkaline in the same or similar tumours (Griffiths, 1991; Negendank, 1992). Thus, the apparent acidity of the extracellular (interstitial) pH (pHe) does not translate to an acidic pHi. Recently, 31P MRS methods have been developed to simultaneously measure the pHi and pHe of tumours using endogenous Pi and exogenous 3-aminopropylphosphonate (3-APP), respectively (Gillies et al, 1994). This method has clearly shown, in a number of solid tumour xenografts, that the pHi of tumour cells is neutral–alkaline, while the pHe of the same tumours is acidic (McCoy et al, 1995; Raghunand et al, 1999a). Thus, solid tumours generally have substantial acid-outside pH gradients.

In the early part of this century, Otto Warburg postulated that tumours were acidic because the rate at which they produced lactic acid was ‘remarkable’ (Warburg, 1956). Subsequent measurement of pH in a variety of solid tumours with microelectrodes apparently confirmed this hypothesis (Wike-Hooley et al, 1984). It is assumed that microelectrode measurements primarily interrogate extracellular (interstitial) volumes. However, in-vivo 31P magnetic resonance spectroscopy (MRS) of endogenous intracellular inorganic phosphate (Pi) measures an intracellular pH (pHi) which is neutral-to-alkaline in the same or similar tumours (Griffiths, 1991; Negendank, 1992). Thus, the apparent acidity of the extracellular (interstitial) pH (pHe) does not translate to an acidic pHi. Recently, 31P MRS methods have been developed to simultaneously measure the pHi and pHe of tumours using endogenous Pi and exogenous 3-aminopropylphosphonate (3-APP), respectively (Gillies et al, 1994). This method has clearly shown, in a number of solid tumour xenografts, that the pHi of tumour cells is neutral–alkaline, while the pHe of the same tumours is acidic (McCoy et al, 1995; Raghunand et al, 1999a). Thus, solid tumours generally have substantial acid-outside pH gradients.

Acid-outside pH gradients have a number of important sequellae that are germane to cancer, including a theoretically reduced partitioning of weakly basic chemotherapeutic drugs and, hence, reduced their cytotoxicity. This phenomenon has been postulated to contribute to a ‘physiological’ resistance to weakly basic drugs in vivo. Doxorubicin is a weak base chemotherapeutic agent that is commonly used in combination chemotherapy to clinically treat breast cancers. This report demonstrates that MCF-7 human breast cancer cells in vitro are more susceptible to doxorubicin toxicity at pH 7.4, compared to pH 6.8. Furthermore 31P-magnetic resonance spectroscopy (MRS) has shown that the pHe of MCF-7 human breast cancer xenografts can be effectively and significantly raised with sodium bicarbonate in drinking water. The bicarbonate-induced extracellular alkalization leads to significant improvements in the therapeutic effectiveness of doxorubicin against MCF-7 xenografts in vivo. Although physiological resistance to weakly basic chemotherapeutics is well-documented in vitro and in theory, these data represent the first in vivo demonstration of this important phenomenon.

Keywords: doxorubicin; acid-base balance; chemotherapy; MRS; bicarbonate

MATERIALS AND METHODS

Cell and tumour growth
MCF-7 cells were obtained from W S Dalton (Arizona Cancer Center) and cultured in RPMI-1640/DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA). For in vivo culturing, a suspension of 5 x 10⁶ MCF-7 cells in 0.05 ml of Hank’s balanced salt solution were implanted in the mammary fat pads of 6- to 7-week-old female severe combined immunodeficient (SCID) mice. Since MCF-7 cells are oestrogen-dependent, 17β-oestradiol pellets (0.72 mg, 60-day release; Innovative Research of America, Sarasota, FL, USA) were subcutaneously implanted in the shoulder region of the mice by means of a 12-gauge trochar (Innovative Research) 2 days prior to tumour inoculation.

Magnetic resonance spectroscopy
Prior to MRS, mice were anaesthetized with a combination of ketamine (72 mg kg⁻¹), xylazine (6 mg kg⁻¹) and acepromazine (6 mg kg⁻¹). A 3/4′′, 24-gauge catheter (Elf Sanofi Inc., Overland Park, KS, USA), connected to a 1.58 mm intradermal (i.d.)
polyethylene tube (Becton Dickinson, Parsippany, NJ, USA), long enough to extend out of the magnet was inserted into the intraperitoneal (i.p.) cavity of the anaesthetized animal. The mouse was then immobilized on a home-built probe with a coil tunable to 1H or 31P. After shimming the magnet, 3-APP (0.15–0.3 mL, 128 mg mL\(^{-1}\), pH 7.4) was injected into the mouse via the i.p. catheter. Volume-selective \(^{31}\)P spectra were acquired at 4.7 T on a Bruker Biospec with the ISIS sequence (Ordidge et al., 1988) with adiabatic slice-selective and excitation pulses repeated every 10–12 s, using a gradient strength of 75 mT m\(^{-1}\). In all cases, a Bruker Biospec with the ISIS sequence (Ordidge et al., 1988) with time the cells were incubated in DMEM/F12 containing 20 mM Doxorubicin uptake and cytotoxicity in vitro

Measurement of intracellular pH in vitro

Intracellular pH (pHi) was measured in vitro using the fluorescent dye, SNARF-1, as described previously (Martinez-Zaguanil et al., 1991). Briefly, MCF-7 cells were grown onto 9 × 22 mm glass coverslips, washed three times with buffer A (1.3 mm calcium chloride, 1 mM magnesium sulphate, 5.4 mM potassium chloride, 0.44 mM KH\(_2\)PO\(_4\), 110 mM sodium chloride, 0.35 mM NaH\(_2\)PO\(_4\), 5 mM glucose, 2 mM glutamine and 5 mM HEPES, 5 mM MES, 10 mM sodium hydrogen carbonate (NaHCO\(_3\)) at a pH of 7.15 at 37°C and subsequently incubated for 30 min at 37°C, in a 5% carbon dioxide atmosphere with 3 mL of buffer A containing 10 mM acetoxymethylester SNARF-1 (Molecular Probes, Eugene, OR, USA). This was followed by a second incubation in buffer A for 45 min to allow for complete hydrolysis of the dye. Coverslips were then placed in a holder/perfusion device and inserted into a fluorometer cuvette and fluorescence measurements were acquired at an excitation of 534 nm with the emission sequentially sampled at 584 and 644 nm in an SLM8000C (SLM, Urbana, IL, USA). The ratio (R) of fluorescence intensities of emissions at 584 and 644 nm in an SLM8000C (SLM, Urbana, IL, USA). The ratio (R) of fluorescence intensities of emissions at 584 and 644 nm was converted to pH\(_i\) values using the equation: pH = 7.38 + log\(_{10}\) 0.822 + log\(_{10}\) [(R – 0.458)/(1.928 – R)]. Data are presented as mean ± s.e.m. of six independent measurements.

Doxorubicin uptake and cytotoxicity in vitro

MCF-7 cells were grown to confluence in 6-well plates at which time the cells were incubated in DMEM/F12 containing 20 mM HEPES, 20 mM MES, 10% FBS and 0.208 μCi per well of 14C doxorubicin (Amersham) for 30 min at 37°C in a 5% carbon dioxide atmosphere at pH of 6.8 and 7.4 respectively. After the incubation, the plates were placed on ice and washed five times with ice-cold HBSS, followed by extraction with 1.0 mL of 0.1 N NaOH for 1 h at 4°C. Samples were divided into equal aliquots for determination of protein content using the Bradford assay (Bio-Rad), and radioactivity using liquid scintillation counting.

Cytotoxicity was determined as previously described (Gillies et al., 1986). Briefly, cells were grown to log phase in 96-well plates and medium was exchanged for one at either pH 6.8 or 7.4 containing the indicated concentrations of doxorubicin. Medium pH was buffered using non-volatile buffers (10 mM MES, 20 mM HEPES and 10 mM TRICINE) in combination with bicarbonate concentrations that were adjusted to be in equilibrium with 5% ambient carbon dioxide. Twenty-four hours later, regular growth medium was replaced and cells allowed to grow a subsequent 72 h, after which time they were fixed and stained with crystal violet for determination of cell number.

Calculation of theoretical drug distributions

Cytoplasmic–extracellular drug ratios were calculated at the steady-state using methods described previously (Roos, 1978; Raghunand et al., 1999b). Briefly, the ratio of protonated (charged) to deprotonated (uncharged) doxorubicin were calculated from the Henderson–Hasselbach equation in both intracellular and extracellular compartments using the pH\(_i\) and pH\(_e\), respectively, and a drug pK\(_a\) of 7.6. The concentration of the uncharged specie was set to 1.0 on both sides of the membrane and the total concentration was calculated as the sum of (charged + uncharged). Data were expressed as a ratio of intra- to extracellular concentrations. Enhancement was calculated as the ratio at high pH, relative to that at low pH.

Tumour growth statistics

Tumour size was measured with calipers and calculated as: (width\(^2\) × length)/2. Data were linearized by converting volumes (in mm\(^3\)) to their cube roots. The least squares regression line of

| Table 1 | Theoretical and measured enhancement of doxorubicin uptake caused by increasing extracellular pH in vitro and in vivo |
|---------|------------------|
| **In vitro** | **Low pH** | **High pH** |
| **Extracellular pH** | 6.8 | 7.4 |
| **Intracellular pH (pH\(_i\))** | 7.05 ± 0.06 (22) | 7.20 ± 0.07 (5) |
| **Theoretical ratio** | 0.69 ± 0.07 | 1.36 ± 0.17 |
| **Theoretical enhancement** | 1.97 ± 0.45 |
| **Doxorubicin uptake (n)** | 65.1 ± 2.7 (6) | 166.9 ± 9.1 (6) |
| **Uptake enhancement** | 2.56 ± 0.25 |
| **EC\(_{50}\) (µM)** | 0.27 | 0.12 |
| **Toxicity enhancement** | 2.25 |

| Table 2 | Tumour growth statistics |
|---------|--------------------------|
| **A** | **B** | **C** | **D** |
| **No. mice** | 17 | 13 | 12 | 13 |
| **T–C (d to 300 mm\(^3\))** | – | – | 15 | 22 |
| **T/C (%)** | – | – | 0.47 | 0.29 |
| **Growth rate (d\(^{-1}\))** | 0.206 | 0.215 | 0.156 | 0.092 |
| **Standard deviation** | 0.094 | 0.060 | 0.067 | 0.047 |
| **P vs group A** | – | 0.732 | 0.031 | 0.002 |
| **P vs group B** | 0.732 | – | 0.027 | 0.001 |
| **P vs group C** | 0.031 | 0.027 | – | 0.008 |
| **P vs group D** | 0.002 | 0.001 | 0.008 | – |
the cube root volumes from day 9 onward were fit for each mouse with non-zero tumour growth. Three-way analyses of variance were used to examine the effect of different experiments, injection (doxorubicin vs saline), and water (plain vs bicarbonate). The differences between experiments were not significant 

(P = 0.767) and, hence, data from all experiments were pooled for further two-way analyses of variance. Tumour cell log kill was calculated from the equation \[ \frac{\text{Number of cells}}{1000} = \frac{T}{C} \], where \(T\) and \(C\) are the number of days it took for treated and control groups, respectively, to reach 1000 mm\(^3\). \(T_d\) is the exponential doubling time of the treated group (Corbett et al., 1982). \(T/C\) was calculated as the ratio of the median volumes of treated and control groups on day 20. \(T/C < 44\%\) is considered significant by the Division of Cancer Treatment (National Cancer Institute), while a \(T/C\) value of \(< 10\%\) (DN-2 level activity) is considered highly significant.

### RESULTS

#### pH affects doxorubicin distribution and cytotoxicity in vitro

Solid tumours generally exhibit pH values of 6.7–6.8 (Wike-Hooley et al., 1984; Griffiths, 1991; Gillies et al., 1994; McCoy et al., 1995; Raghunand et al., 1996a). In vitro, MCF-7 cells at medium pH values of 6.8 and 7.4 have pH values of 7.05 ± 0.06 and 7.20 ± 0.07, respectively, as measured with fluorescence (Figure 1A). Thus, according to theory (see Methods), the pH gradient of +0.25 at pH = 6.8 will yield an intracellular–extracellular doxorubicin ratio of \(0.69 \pm 0.07\), whereas at pH = 7.4, the ratio will be \(1.36 \pm 0.17\) (Table 1). Hence, there will be a \(1.97 \pm 0.45\)-fold enhancement of the steady-state intracellular drug concentration as pH is raised from 6.8 to 7.4. The empirical steady-state levels of \(^{14}\)C doxorubicin in MCF-7 cells at medium pH values of 6.8 and 7.4 show a 2.56 ± 0.25-fold enhancement (Figure 1B), which is in good agreement with theory.

The difference in intracellular levels of doxorubicin between low and high pH values should give rise to differences in cytotoxicity. Figure 1C shows that, following a 24-h treatment, the EC\(_{50}\) of doxorubicin in MCF-7 cells is 0.27 μm at pH 6.8, compared to 0.12 μm at pH 7.4. One-hour treatments with doxorubicin yielded essentially the same results, although both EC\(_{50}\) values were higher. Similar data for doxorubicin have been reported elsewhere (Tannock and Rotin, 1989; Simon and Schindler, 1994). In the current study, the 2.25-fold enhancement of doxorubicin cytotoxicity at pH 7.4 compared to pH 6.8 is similar in magnitude to both theory and the empirical doxorubicin distribution ratio (cf. Table 1). Thus, the enhanced cytotoxicity at high pH is likely due to increased partitioning of doxorubicin into cells.

#### Bicarbonate raises pH in vivo

While there is substantial evidence that doxorubicin is more effective at higher pH, this phenomenon is of limited utility unless the pH of tumours can be manipulated in vivo. For the current experiments, pH was raised via sodium bicarbonate-induced metabolic alkalosis. However, the addition of bicarbonate could have important negative sequelae, since it is osmotically active and could cause hypernatraemia. To determine the maximum tolerated doses of bicarbonate, eight different cohorts of SCID mice were given NaHCO\(_3\)-supplemented water to drink ad libitum. Bicarbonate concentrations ranged from 0 to 250 mM. Animal weights and water consumption were monitored daily. For bicarbonate concentrations up to 225 mM, weight gain and subjective parameters (e.g., grooming behaviour and activity) were unaffected compared to water controls for up to 9 weeks (data not shown). In a separate experiment, animals were given 200 mM NaHCO\(_3\), ad lib. Four to 10 days following commencement of bicarbonate therapy, pH and pHe were measured using \(^{31}\)P MRS. A representative \(^{31}\)P spectrum from an untreated MCF-7 cell tumour is shown in Figure 2A. In this Figure, the pH measured by 3-APP resonance from a representative \(^{31}\)P MRS spectrum of...
MCF-7 tumours obtained 4 days following substitution of drinking water with 200 mM NaHCO₃. Note the shift in the position of the 3-APP resonance relative to controls indicating a significant alkalinization of pH. All other resonances (Pi, PME, ATP) were statistically indistinguishable from the controls. In this example, the measured pHₑ was 7.72. Thus, NaHCO₃ can significantly increase pHₑ.

Results from all of the MRS-based pH measurements are shown in Figure 3A, expressed as a function of tumour size. Note that in untreated MCF-7 tumours (triangles), the pHₑ (open) and pHᵢ (closed) decrease with approximately the same slope with increasing tumour size. Thus, the pH gradient is relatively constant at 0.22 ± 0.09 pH unit, consistent with previous reports (Raghunand et al, 1999a). In animals supplemented with HCO₃⁻, the measured pHₑ values (open circles) are significantly higher than the measured pHᵢ values (closed circles). This is significantly different than the pHₑ and pHᵢ of control animals. The direction of the plasmalemmal (in–out) pH gradient is shown by arrows in the Figure and it is clear that the direction is reversed in all NaHCO₃-treated animals, compared to controls. The pHₑ reported by the 3-APP resonance in NaHCO₃-treated tumours is high, 7.84 ± 0.13 pH unit. The pHᵢ values in the same animals were 7.39 ± 0.12. The imprecision in both the pHₑ and pHᵢ measurements are likely higher due to these values being near the alkaline extreme of the titration curves for both 3-APP and Pi respectively. Nevertheless, the data clearly show that chronic bicarbonate therapy effectively alkalinizes the pHₑ in vivo, generating an (in–out) ΔpH of approximately – 0.45 pH unit, compared to a ΔpH of + 0.20 in untreated animals.

**Bicarbonate chemosensitizes tumour xenografts in vivo**

According to the measured pH gradients, the theoretical cytosolic–extracellular drug ratio should be 1.6 in bicarbonate-treated animals, and 0.6 in controls, leading to a 2.5-fold increase in doxorubicin sensitivity (Table 1). To test this, MCF-7 tumours were grown in the mammary fat pads of 6-week-old female SCID mice, to sizes of 50–200 mm³, and were forcibly randomized according to tumour size into four groups. Groups A and C were given normal water ad libitum, while the water given to groups B and D was supplemented with 200 mM NaHCO₃. The start of the bicarbonate treatment was designated as day 1. On days 3, 7 and 11, animals in groups C and D (n = 10 each) received saline injections of the same volume, as per established protocols (Paine-Murrieta et al, 1997). The maximum tolerated dose (MTD) of SCID mice for doxorubicin under this regimen is a cumulative 6.7 mg kg⁻¹ (Paine-Murrieta et al, 1997). Initial experiments used three doses of doxorubicin at 2.0 mg kg⁻¹ (cohorts C₁/D₁) and this was reduced in later experiments to three doses at 1.6 mg kg⁻¹ (cohorts C₂/D₂) to reduce morbidity. In all
experiments, the incidence of morbidity following drug treatment was identical between groups C and D. In parallel experiments, three doses of i.p. doxorubicin at 2.0 mg kg\(^{-1}\) on days 1, 5 and 9 gave no evidence of vesication upon day 10 necropsy. Tumour volumes and animal weights were monitored every 2–3 days. For graphing purposes, tumour volumes for each mouse were normalized to day 1. As shown in Figure 3B, doxorubicin has a significant effect on the tumour growth rate, and this effect is greater in animals co-treated with bicarbonate. For statistical analyses, normalized data were used to calculate specific tumour growth rates for each tumour, from day 9 onward. The means of these normalized tumour growth rates are shown in Figure 3C. Regardless of dose, the tumour growth rate was significantly (\(P \leq 0.03\)) slower in the bicarbonate plus doxorubicin groups (D\(_1\), D\(_2\)) compared to the doxorubicin alone groups (C\(_1\), C\(_2\)) (Table 2). Furthermore, bicarbonate alone had no significant effect on the growth rate (\(P > 0.4\), A vs B). Table 2 also shows that the tumour growth delays (T–C) were 15 and 22 days at 300 mm\(^3\) for groups C and D respectively. However, since the slopes of the growth curves diverge, the T–C increased with time, and thus cannot be used to
DISCUSSION
These data indicate that raising pH increased the cytotoxic effectiveness of doxorubicin both in vitro and in vivo. In-vitro, raising the pH from 6.8 to 7.4 resulted in a 2.25-fold enhancement of cytotoxicity and a 2.56-fold increase in intracellular doxorubicin concentrations. These data compared well to the 1.97-fold enhancement predicted from the calculated difference in doxorubicin distributions (Table 1). It is possible that the larger enhancement observed empirically, relative to theory, is due to sequestration of doxorubicin in acidic vesicles, which was not accounted for in the theoretical calculations (Altan et al, 1998; Raghunand et al, 1999b).

In vivo, in the SCID mouse–MCF7 tumour model system used here, the data clearly show that NaHCO3 effectively raises the pH for extended periods of time. Prolonged treatments with bicarbonate in drinking water did not have significant effects on animal well-being.

Nevertheless, for bicarbonate therapy to have clinical utility, the minimum required treatment time needs to be determined. Previous protocols involving bicarbonate treatment of humans have primarily been developed to counteract acidosis caused by exercise or renal failure (Passfall et al, 1997; Verbitsky et al, 1997). A problem in these protocols is poor patient compliance, with chronic bicarbonate ingestion. Clinical metabolic alkalinization with bicarbonate will be most successful if it is administered acutely, viz. shortly prior to the time of chemotherapy. Hence, experiments are underway to determine the time course of alkalinization and whether acute, intermittent alkalinization is as effective, compared to chronic bicarbonate administration.

Combination therapy with bicarbonate and doxorubicin resulted in a significantly lowered tumour growth rate compared to treatment with doxorubicin alone. In SCID mice, as in human patients, doxorubicin alone is not a highly effective cytotoxic agent with much heterogeneity of response. Many workers have used SCID mice to test doxorubicin chemotherapy (Liu et al, 1996; Cesano et al, 1997; Durand and LePard, 1997). A recent report indicates that doxorubicin is not effective to treat tumours in SCID mice, due to granulocyte toxicity to the host (Polin et al, 1997). This may be observed in our studies, since the tumour outgrowth did not occur with the same doubling time as the untreated tumours. Consequently, log kill values could not be reliably calculated. However, the T/C value measured at day 20 was 0.29 for group D, compared to 0.47 for group C. T/C < 44% is considered significant by the Division of Cancer Treatment (NCI). Thus, this measure indicates a meaningful boost in therapeutic effectiveness caused by raising the pH with bicarbonate. In other systems, such as syngeneic mice (16C mammary adenocarcinoma in C3H mice), log kill from doxorubicin can be 2.5–3.0 (T Corbett, personal communication). Hence, experiments are planned using this more responsive mouse system, even though it is not a high connectivity model for human clinical response.

The growth rates resulting from the two different doxorubicin doses were not significantly different (i.e. C1 vs C2, D1 vs D2). However, the lower doxorubicin dose did reduce the mortality of the treated animals during the course of the experiments. At 2 mg kg–1, half of the animals survived in both groups to day 30. At 1.6 mg kg–1, only one animal from each group (out of eight) did not survive until day 30. It must be noted that doxorubicin-treated animals appeared more distressed than controls. By day 15, animals in groups C and D displayed poor grooming and urinary discharges. By day 30, all animals in group D were experiencing anal discharge as well. This suggests that, in addition to the tumours, bicarbonate also sensitized the intestinal epithelium to doxorubicin cytotoxicity. Since bicarbonate should only have this effect on tissues with low initial pH, this might indicate that intestinal epithelial cells or colonic crypts have a naturally low pH. This side-effect of combination bicarbonate–doxorubicin chemotherapy might be avoided with shorter bicarbonate treatment times, more selective alkalinizing agents, or protection of the intestinal epithelium with acid buffers or V-ATPase inhibitors. Despite the qualitatively poorer condition of group D animals, there was no significant difference in their body weights, compared to animals of group C.

Our calculations predict that alkalinization should provide a two- to threefold increase in the therapeutic efficacy of doxorubicin. This is significant, because many current clinical studies indicate that threefold accelerated dosing of doxorubicin is more effective in treating node-positive breast cancers (Bearman et al, 1997). However, doxorubicin has associated cardiotoxicity and there is a significant morbidity associated with accelerated dosing regimens. Thus, if two- to threefold increases in cytosolic doxorubicin could be achieved through manipulation of pH, it is likely that the therapeutic benefits could be realized without the increased morbidity associated with accelerated dosing.

In summary, the current data indicate that the pH of human breast tumour xenografts is acidic and that this reduces the cytotoxicity of doxorubicin in vitro and in vivo. Tumour pH can be chronically raised by treatment with sodium bicarbonate in the drinking water of tumour-bearing SCID mice, and this significantly increases the chemotherapeutic efficacy of doxorubicin chemotherapy in vivo.

ACKNOWLEDGEMENTS
The authors would like to thank J-P Galons for helpful discussions, L Celaya for secretarial assistance, and TH Corbett, J Evelhoch and S Salmon for thoughtful evaluations of the manuscript. Support from the US Army Breast Cancer Initiative grants DAMD-17-94-J-4368 (RIG) and DAMD-17-96-1-6131 (ZMB) and NIH RO1-CA23074 is also gratefully acknowledged.

REFERENCES
Altan N, Chen Y, Schindler M and Simon SM (1998) Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 187: 1583–1598
Bearman SI, Overmoyer BA, Bolwell BJ, Taylor CW, Shpall EJ, Cagnoni PJ, Mechling BE, Ronk B, Baron AE, Purdy MH, Ross M and Jones RB (1997) High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodes. Bone Marrow Transplant 20: 931–937
Cesano A, Visonneau S, Rovera G and Santoli (1997) Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo. Anticancer Res 17: 1887–1892
Corbett TH, Roberts BJ, Trader MW, Laster WR Jr, Geiswohl DPJ and Schabel FM Jr. (1982) Response of transplantable tumors of mice to anthracycinedione derivatives alone and in combination with clinically useful agents. *Cancer Treat Rep* 66: 1187–1200

Durand RE and LePard NE (1997) Tumour blood flow influences combined radiation and doxorubicin treatments. *Radiother Oncol* 42: 171–179

Gillies RJ and Deamer DW (1978) Intracellular pH: methods and applications. *Curr Top Bioenergetics* 9: 63–87

Gillies RJ, Didier N and Denton M (1986) Determination of cell number in monolayer cultures. *Analyst Biochem* 159: 109–113

Gillies RJ, Liu Z and Bhujwalla Z (1994) 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. *Am J Physiol* 195: 203

Griffiths JR (1991) Are cancer cells acidic? *Br J Cancer* 64: 425–427

Liu C, Lambert JM, Teicher BA, Blattler WA and O’Connor R (1996) Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. *Blood* 87: 3892–3898

Martinez-Zaguilan R, Martinez GM, Lattanzio F and Gillies RJ (1991) Simultaneous measurement of intracellular pH and Ca2+ using the fluorescence of SNARF-1 and Fura-2. *Am J Physiol* 260: C297–C307

McCoy CL, Parkins CS, Chaplin DJ, Griffiths JR, Rodrigues LM and Stubbs M (1995) The effect of blood flow modification on ontra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. *Br J Cancer* 72: 27–30

Negendank W (1992) Studies of human tumors by MRS: a review. *NMR Biomed* 5: 27–30

Ordidge RJ, Bowley RM and McHale G (1988) A general approach to selection of multiple cubic volume elements using the ISIS technique. *Magn Reson Med* 8: 323–331

Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MHA, Dorr RT, Johnson CS, Funk CY, Thompson F and Hersh EM (1997) Human tumor models in the severe combined immune deficient (Scid) mouse. *Cancer Chemother Pharmacol* xx: 1–6

Passfall J, Pai J, Spies KP, Haller H and Luft FC (1997) Effect of water and bicarbonate loading in patients with chronic renal failure. *Clin Nephrol* 47: 92–98

Polin L, Valeriote F, White K, Panchap Pugh S, Knight J, LoRusso, Hussain M, Liveridge E, Peltier N, Golakoti T, Patterson G, Moore and Corbett TH (1997) Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. *Invest New Drugs* 15: 99–108

Raghunand N, Altbach MI, Van Shuis R, Baggett B, Taylor CW, Bhujwalla ZM and Gillies RJ (1999a) Plasmaemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P MR spectroscopy. *Biopharm Pharmacol* 57: 309–312

Raghunand N, Martinez-Zaguilan R, Wright SH and Gillies RJ (1999b) pH and drug resistance II: turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. *Biochem Pharmacol* 57: 1047–1058

Roos A (1978) Weak acids, weak bases, and intracellular pH. *Respir Physiol* 33: 27–30

Simon SM and Schindler M (1994) Cell biological mechanisms of multidrug resistance in tumors. *Proc Natl Acad Sci USA* 91: 3497–3504

Tannock IF and Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. *Cancer Res* 49: 4373–4384

Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ and Trent JM (1991) Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. *Br J Cancer* 63: 923–929

Verbitsky O, Mizrahi J, Levin M and Isakov E (1997) Effect of ingested sodium bicarbonate on muscle force, fatigue, and recovery. *J Appl Physiol* 83: 333–337

Warburg O (1956) On the origin of cancer cells. *Science* 123: 309–314

Wike-Booley J, Haveman J and Reinhold HS (1984) The relevance of tumour pH to the treatment of malignant disease. *Radiother Oncol* 2: 343–366